US regulators order warnings on GLP-1 drugs over blindness risk

The FDA's directive requires drugmakers to include information about nonarteritic anterior ischemic optic neuropathy, or NAION, a condition affecting blood flow to the optic nerve that can result in sudden blindness. The regulatory action affects a class of medications known as GLP-1 receptor agonists, which have surged in popularity for both diabetes management and weight reduction in recent years.

Ozempic, manufactured by Novo Nordisk and approved for diabetes treatment, and Wegovy, the company's weight-loss formulation, are among the medications affected by the labeling requirement. The warning is intended to alert patients and healthcare providers to monitor for symptoms including sudden vision changes or eye pain, particularly in individuals with existing risk factors for the condition.

NAION is a rare vascular condition that typically occurs in older patients with underlying health conditions such as diabetes and hypertension. The FDA's action follows reports linking the use of GLP-1 drugs to cases of the eye condition, prompting the agency to evaluate the safety data and determine that updated labeling was warranted to ensure informed medical decision-making.

The GLP-1 drug class has become increasingly prevalent globally, with healthcare providers prescribing these medications to millions of patients. The addition of warning labels represents the FDA's effort to balance the therapeutic benefits of these widely-used drugs with the need to communicate potential risks to patients and their physicians.